StockNews.com Begins Coverage on Tenax Therapeutics (NASDAQ:TENX)

StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a report published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, Roth Mkm reissued a buy rating and issued a $6.00 price objective on shares of Tenax Therapeutics in a research report on Monday, November […]

Leave a Reply

Your email address will not be published.

Previous post 2seventy bio (NASDAQ:TSVT) Earns “Outperform” Rating from Wedbush
Next post BioCardia (NASDAQ:BCDA) Given “Buy” Rating at HC Wainwright